Apogee Therapeutics (APGE) Goldman Sachs 45th Annual Global Healthcare Conference summary

Strategic priorities and pipeline focus

• Developing advanced monotherapies and combination therapies targeting large I&I markets, including atopic dermatitis, COPD, and asthma.

• Lead program aims for a SKYRIZI-like 3-6 month dosing profile in atopic dermatitis, with proof-of-concept PK data for an IL-4 receptor alpha antibody expected in the second half of the year.

• Plans to share more on combination approaches and new targets, with an R&D day scheduled for the second half of the year.

• Long-term strategy includes first-in-class, best-in-class potential through co-formulation of monotherapies, maintaining extended dosing intervals.

• Focus on rapid execution, pipeline expansion, and maintaining a competitive edge in combination therapies.

Intellectual property and differentiation

• Built on a strong FTO and patentability foundation, with significant investment in non-human primate studies to create superior antibodies.

• Initial IP has been published, with ongoing filings to protect composition and maintain defensibility.

• Emphasis on non-obvious solutions to meet patent examiner standards and ensure robust IP protection.

Clinical development and trial design

• Integrated phase IIa/IIb trial for lead asset 777 in atopic dermatitis, with 6-week induction data expected in the second half of next year and 52-week maintenance data to follow.

• Phase II exposure designed to exceed lebrikizumab by 30%-40% in induction, aiming for improved efficacy and reduced injection burden.

• Maintenance data generated early to inform phase III design and accelerate development, supported by strong cash reserves for at-risk investments.